Detection of cache valley virus in biologics manufactured in CHO cells

BioPharm International

Volumn 21, Issue 10, 2008, Pages 89-96

  Nims, Raymond W ^a,c   Dusing, Sandra K ^a   Hsieh, Wang Ting ^a   Lovatt, Archie ^b   Reid, G Gordon ^b   Onlons, David ^b   Milne, Euan W ^b  

^a BioReliance   (United States)

^b BioReliance Ltd   (United Kingdom)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN;

ARTICLE; BUNYAVIRUS; CACHE VALLEY BUNYAVIRUS; CELL GROWTH; CHO CELL; CULTURE MEDIUM; DRUG MANUFACTURE; FOOD AND DRUG ADMINISTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PROCESS MONITORING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSMISSION ELECTRON MICROSCOPY; VIRAL CONTAMINATION; VIRUS DETECTION; VIRUS IDENTIFICATION; VIRUS ISOLATION; VIRUS LOAD;

EID: 56249104810     PISSN: 1542166X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Hojman F, et al. Biological and molecular characterization of an endogenous retrovirus present in CHO/HBs - A Chinese hamster cell line. Dev Biol Stand. 1989;70:195-202.
2. Dinowitz M, et al. Recent studies on retrovirus-like particles in Chinese hamster ovary cells. Dev Biol Stand. 1992;76:210-207.
3. Garnick RL. Experience with viral contamination in cell culture. Dev Biol Stand. 1996;88:49-6.
4. Nims RW. Detection of adventitious viruses in biologicals - A rare occurrence. Dev Biol. 2006;123:153-164.
5. US FDA. Points to consider in the characterization of cell lines used to produce biologicals. FDA/CBER, 1993.
6. US FDA. Points to consider in the manufacture and testing of monoclonal antibody products for human use. FDA/CBER, 1997.
7. Gonzalez-Scarano F, Nathanson N. Bunyaviridae. In: Fields BN, Knife DM, Howley PM, editors. Fields Virology, 3rd edition, Philadelphia, PA: Lippincott-Raven; 1996. p.1473-1504.
8. Blackmore CG, Grimstad PR. Cache Valley and Potosi viruses (Bunyaviridae) in white-tailed deer (Odocoileus virginianus): experimental infections and antibody prevalence in natural populations. Am J Trop Med Hyg. 1998;59:704-709.
9. Sahu SP, et al. Serologic survey of cattle in the northeastern and north central United States, Virginia, Alaska, and Hawaii for antibodies to Cache Valley and antigenically related viruses. Am J Trop Med Hyg. 2002;67:119-122.
10. McLean RG, Callsher CH, Parham GL. Isolation of Cache Valley virus and detection of antibody for selected arboviruses in Michigan horses in 1980. Am J Vet Res 1987;48:1039-1041.
11. Buescher EL, et al. Cache Valley virus in the Del Mar Va Peninsula. I. Virologic and serologic evidence of infection. Am J Trop Med Hyg. 1970;19:493-502.
12. Sexton DJ, et al. Life-threatening Cache Valley virus infection. N Engl J Med. 1997;336:547-550.
13. Campbell GL, et al. Second human case of Cache Valley virus disease. Emerg Infect Dis. 2006;12:854-856.
14. Nims R, et al. Adventitious agents: Concerns and testing for biopharmaceuticals. In: Rathore AS, Sofer G, editors. Process validation in manufacturing of biopharmaceuticals: guidelines, current practices, and industrial case studies. Boca Raton, FL: CRC Press/Francis Informa; 2005. p. 143-67.
15. Powell JW. Personal communication.
16. Onions D, unpublished data.